Showing 2766 results
- Media Release /Results from year two of the Phase III KESTREL clinical trial confirmed year one findings, with an overall favorable benefit-risk profile for Beovu® (brolucizumab) 6 mg in patients with visual…
- Media Release /Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2-…
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Library /
- Media Release /Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to…
- Media Release /Basel, December 6, 2021 — The bilateral transaction between Novartis and Roche for the sale of 53.3 million (approximately 33%) Roche bearer shares has successfully closed today, December 6, 2021.…
- Media Release /All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO…
Pagination
- ‹ Previous page
- 1
- …
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- …
- 277
- › Next page